Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.

ABSTRACT:

Objective

Iron deficiency is a common complication in patients with IBD and oral iron therapy is suggested to exacerbate IBD symptoms. We performed an open-labelled clinical trial to compare the effects of per oral (PO) versus intravenous (IV) iron replacement therapy (IRT).

Design

The study population included patients with Crohn's disease (CD; N=31), UC (N=22) and control subjects with iron deficiency (non-inflamed, NI=19). After randomisation, participants received iron sulfate (PO) or iron sucrose (IV) over 3 months. Clinical parameters, faecal bacterial communities and metabolomes were assessed before and after intervention.

Results

Both PO and IV treatments ameliorated iron deficiency, but higher ferritin levels were observed with IV. Changes in disease activity

SUBMITTER: Lee T 

PROVIDER: S-EPMC5531225 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature